Bausch Health Companies (TSE:BHC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bausch Health Companies Inc. has successfully defended its patent for XIFAXAN (rifaximin) 550 mg as the U.S. Court of Appeals affirmed a decision preventing FDA approval of a generic version by Norwich Pharmaceuticals until October 2029. Despite this win, the court invalidated certain patents for the drug’s use in treating IBS-D, a point the company plans to contest while continuing to prioritize patient safety and access to the medication.
For further insights into TSE:BHC stock, check out TipRanks’ Stock Analysis page.